2026-06-14T03:43:00Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/163072024-09-27T23:13:28Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Hanquet, Germaine author Kissling, Esther author Fenoll, Asuncion author George, Robert author Lepoutre, Agnes author Lernout, Tinne author Tarrago Asensio, David author Varon, Emmanuelle author Verhaegen, Jan author 2010-09 After heptavalent pneumococcal conjugate vaccine (PCV7) was marketed in France, Spain, Belgium, and England and Wales (United Kingdom), invasive disease from non-PCV7 serotypes (NVT) increased. Adjusted serotype-specific incidences among children <15 years of age were compared between 1999-2002 (prevaccine) and 2005-2006 (postmarketing). Vaccine coverage increased to approximately 32%-48% in France, Spain, and Belgium but remained <1% in England and Wales. Serotype 1 incidence rose in all age groups and countries (incidence rate ratio [IRR] 1.3-4.2; p<0.004), independently of PCV7 use, but incidence of serotypes 7F and 19A increased most in France, Spain, and Belgium (IRR 1.9-16.9 in children <5 years; p<0.001), where PCV7 coverage was greater. Vaccine-induced replacement of PCV7 serotypes possibly contributed to NVT increases, as did secular trends. New vaccines targeting these serotypes are available, but serotype dynamics needs further exploration that accounts for underreporting and prevaccine trends. Emerg Infect Dis. 2010 Sep;16(9):1428-39. 10.3201/eid1609.100102 1080-6059 Emerging infectious diseases 20735928 http://hdl.handle.net/20.500.12105/16307 Pneumococcal serotypes in children in 4 European countries